Yasuhito Kotake1,2, Sumita Barua1, Samia Kazi1, Sohaib Virk1, Ashwin Bhaskaran1,2, Timothy Campbell1,2, Richard G Bennett1,2, Saurabh Kumar3,4. 1. Department of Cardiology, Westmead Hospital, Westmead, NSW, Australia. 2. Westmead Applied Research Centre, University of Sydney, Westmead, NSW, Australia. 3. Department of Cardiology, Westmead Hospital, Westmead, NSW, Australia. saurabh.kumar@health.nsw.gov.au. 4. Westmead Applied Research Centre, University of Sydney, Westmead, NSW, Australia. saurabh.kumar@health.nsw.gov.au.
Abstract
BACKGROUND: Patients with Brugada syndrome (BrS) may experience recurrent ventricular arrhythmias (VAs). Catheter ablation is becoming an emerging paradigm for treatment of BrS. OBJECTIVE: To assess the efficacy and safety of catheter ablation in BrS in an updated systematic review. METHODS: We comprehensively searched the databases of Pubmed/Medline, EMBASE, and Cochrane Central Register of Controlled Trials from inception to 11th of August 2021. RESULTS: Fifty-six studies involving 388 patients were included. A substrate-based strategy was used in 338 cases (87%), and a strategy of targeting premature ventricular complex (PVCs)/ventricular tachycardias (VTs) that triggered ventricular fibrillation (VF) in 47 cases (12%), with combined abnormal electrogram and PVC/VT ablation in 3 cases (1%). Sodium channel blocker was frequently used to augment the arrhythmogenic substrate in 309/388 cases (80%), which included a variety of agents, of which ajmaline was most commonly used. After ablation procedure, the pooled incidence of non-inducibility of VA was 87.1% (95% confidence interval [CI], 73.4-94.3; I2 = 51%), and acute resolution of type I ECG was seen in 74.5% (95% CI [52.3-88.6]; I2 = 75%). Over a weighted mean follow up of 28 months, 7.6% (95% CI [2.1-24]; I2 = 67%) had recurrence of type I ECG either spontaneously or with drug challenge and 17.6% (95% CI [10.2-28.6]; I2 = 60%) had recurrence of VA. CONCLUSION: Catheter ablation appears to be an efficacious strategy for elimination of arrhythmias or substrate associated with BrS. Further study is needed to identify which patients stand to benefit, and optimal provocation protocol for identifying ablation targets.
BACKGROUND: Patients with Brugada syndrome (BrS) may experience recurrent ventricular arrhythmias (VAs). Catheter ablation is becoming an emerging paradigm for treatment of BrS. OBJECTIVE: To assess the efficacy and safety of catheter ablation in BrS in an updated systematic review. METHODS: We comprehensively searched the databases of Pubmed/Medline, EMBASE, and Cochrane Central Register of Controlled Trials from inception to 11th of August 2021. RESULTS: Fifty-six studies involving 388 patients were included. A substrate-based strategy was used in 338 cases (87%), and a strategy of targeting premature ventricular complex (PVCs)/ventricular tachycardias (VTs) that triggered ventricular fibrillation (VF) in 47 cases (12%), with combined abnormal electrogram and PVC/VT ablation in 3 cases (1%). Sodium channel blocker was frequently used to augment the arrhythmogenic substrate in 309/388 cases (80%), which included a variety of agents, of which ajmaline was most commonly used. After ablation procedure, the pooled incidence of non-inducibility of VA was 87.1% (95% confidence interval [CI], 73.4-94.3; I2 = 51%), and acute resolution of type I ECG was seen in 74.5% (95% CI [52.3-88.6]; I2 = 75%). Over a weighted mean follow up of 28 months, 7.6% (95% CI [2.1-24]; I2 = 67%) had recurrence of type I ECG either spontaneously or with drug challenge and 17.6% (95% CI [10.2-28.6]; I2 = 60%) had recurrence of VA. CONCLUSION: Catheter ablation appears to be an efficacious strategy for elimination of arrhythmias or substrate associated with BrS. Further study is needed to identify which patients stand to benefit, and optimal provocation protocol for identifying ablation targets.
Authors: Silvia G Priori; Arthur A Wilde; Minoru Horie; Yongkeun Cho; Elijah R Behr; Charles Berul; Nico Blom; Josep Brugada; Chern-En Chiang; Heikki Huikuri; Prince Kannankeril; Andrew Krahn; Antoine Leenhardt; Arthur Moss; Peter J Schwartz; Wataru Shimizu; Gordon Tomaselli; Cynthia Tracy Journal: Heart Rhythm Date: 2013-08-30 Impact factor: 6.343
Authors: Carlo Pappone; Josep Brugada; Gabriele Vicedomini; Giuseppe Ciconte; Francesco Manguso; Massimo Saviano; Raffaele Vitale; Amarild Cuko; Luigi Giannelli; Zarko Calovic; Manuel Conti; Paolo Pozzi; Andrea Natalizia; Simonetta Crisà; Valeria Borrelli; Ramon Brugada; Georgia Sarquella-Brugada; Marco Guazzi; Alessandro Frigiola; Lorenzo Menicanti; Vincenzo Santinelli Journal: Circ Arrhythm Electrophysiol Date: 2017-05
Authors: Josep Brugada; Carlo Pappone; Antonio Berruezo; Gabriele Vicedomini; Francesco Manguso; Giuseppe Ciconte; Luigi Giannelli; Vincenzo Santinelli Journal: Circ Arrhythm Electrophysiol Date: 2015-08-19
Authors: Giulio Conte; Juan Sieira; Giuseppe Ciconte; Carlo de Asmundis; Gian-Battista Chierchia; Giannis Baltogiannis; Giacomo Di Giovanni; Mark La Meir; Francis Wellens; Jens Czapla; Kristel Wauters; Moises Levinstein; Yukio Saitoh; Ghazala Irfan; Justo Julià; Gudrun Pappaert; Pedro Brugada Journal: J Am Coll Cardiol Date: 2015-03-10 Impact factor: 24.094
Authors: Michel Haïssaguerre; Fabrice Extramiana; Mélèze Hocini; Bruno Cauchemez; Pierre Jaïs; Jose Angel Cabrera; Jerónimo Farré; Gerónimo Farre; Antoine Leenhardt; Prashanthan Sanders; Christophe Scavée; Li-Fern Hsu; Rukshen Weerasooriya; Dipen C Shah; Robert Frank; Philippe Maury; Marc Delay; Stéphane Garrigue; Jacques Clémenty Journal: Circulation Date: 2003-08-18 Impact factor: 29.690
Authors: Koonlawee Nademanee; Hariharan Raju; Sofia V de Noronha; Michael Papadakis; Laurence Robinson; Stephen Rothery; Naomasa Makita; Shinya Kowase; Nakorn Boonmee; Vorapot Vitayakritsirikul; Samrerng Ratanarapee; Sanjay Sharma; Allard C van der Wal; Michael Christiansen; Hanno L Tan; Arthur A Wilde; Akihiko Nogami; Mary N Sheppard; Gumpanart Veerakul; Elijah R Behr Journal: J Am Coll Cardiol Date: 2015-11-03 Impact factor: 24.094